<p>结构治疗公司（Structure Therapeutics Inc.）赞助的美国存托股票（NASDAQ:GPCR - 获取免费报告）目前获得了 14 家覆盖该股票的券商一致推荐的 “适度买入” 评级，MarketBeat 报道称。两名研究分析师给予该股票卖出评级，十一名给予买入评级，一名给予强烈买入评级。在过去一年中，给予该股票评级的券商的平均 12 个月目标价为 99.1111 美元。</p>
<p>获取 <strong>结构治疗</strong> 的提醒：</p>
<ul>
<li>罗氏能否在减肥市场挑战礼来和诺和诺德？</li>
</ul>
<p>一些股票研究分析师最近对 GPCR 股票进行了评估。HC Wainwright 在 12 月 19 日的报告中将结构治疗的目标价从 60.00 美元上调至 90.00 美元，并给予该公司 “买入” 评级。Lifesci Capital 在 9 月 8 日的报告中将结构治疗的股票升级为 “强烈买入” 评级。花旗集团在 12 月 12 日的报告中重申了对结构治疗股票的 “跑赢大盘” 评级。Piper Sandler 在 10 月 28 日的报告中重新发布了对结构治疗股票的 “增持” 评级。最后，Zacks Research 在 10 月 17 日的研究报告中将结构治疗的评级从 “持有” 下调至 “强烈卖出”。</p>
<p><strong>查看我们对结构治疗的最新分析</strong></p>
<h2>结构治疗股票下跌 1.9%</h2>
<ul>
<li>诺和诺德的挫折不会持续：一款改变游戏规则的药物出现</li>
</ul>
<p>GPCR 股票在周四开盘价为 69.95 美元。该公司的 50 日移动平均线为 41.18 美元，200 日移动平均线为 28.21 美元。结构治疗的 1 年最低价为 13.22 美元，1 年最高价为 94.90 美元。该公司的市值为 42.4 亿美元，市盈率为-57.33，贝塔值为-1.64。</p>
<p>结构治疗（NASDAQ:GPCR - 获取免费报告）最近在 11 月 6 日发布了其财报。公司报告季度每股收益（EPS）为（0.37）美元，低于市场共识预期的（0.36）美元，差距为（0.01）美元。卖方分析师预测结构治疗在本年度将发布-0.82 美元的每股收益。</p>
<h2>结构治疗的机构交易</h2>
<ul>
<li>Altimmune 股票：它的 GLP-1 药物是下一个 Ozempic 杀手吗？</li>
</ul>
<p>一些对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Invesco Ltd.在第一季度将其在结构治疗的持仓增加了 6.1%。Invesco Ltd.目前拥有 394,386 股该公司的股票，价值 6,827,000 美元，此前在上个季度增持了 22,619 股。Quantbot Technologies LP 在第一季度获得了结构治疗的新股份，价值约 249,000 美元。Jump Financial LLC 在第一季度购买了结构治疗的新股份，价值 532,000 美元。Trexquant Investment LP 在第一季度将其在结构治疗的持仓增加了 127.6%。Trexquant Investment LP 目前拥有 120,340 股该公司的股票，价值 2,083,000 美元，此前在上个季度增持了 67,464 股。最后，DAFNA Capital Management LLC 在第一季度将其在结构治疗的持仓增加了 66.2%。DAFNA Capital Management LLC 目前拥有 59,000 股该公司的股票，价值 1,021,000 美元，此前在上个季度增持了 23,500 股。91.78% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>结构治疗公司简介</h2>
<p>（获取免费报告）</p>
<p>结构治疗（NASDAQ: GPCR）是一家临床阶段的生物技术公司，专注于发现和开发针对 G 蛋白偶联受体（GPCRs）的口服小分子疗法。该公司利用结构生物学、计算化学和药物化学的进展，科学平台旨在优化结合相互作用和药代动力学特性，目标是提供创新的代谢和炎症疾病治疗方案。</p>
<p>该公司的产品管线包括多个处于临床前和临床开发不同阶段的项目。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比结构治疗更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘记 AI 吧，这将是下一个重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1BDUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1BDUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在结构治疗吗？</h2>
<p>在考虑结构治疗之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而结构治疗并不在名单上。</p>
<p>虽然结构治疗目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GPCR

<p>Structure Therapeutics Inc.（纳斯达克代码：GPCR）获得了 14 家券商的共识 “适度买入” 推荐。两位分析师给予 “卖出” 评级，十一位分析师给予 “买入” 评级，一位分析师给予 “强烈买入” 评级。12 个月的平均目标价为 99.11 美元。最近的分析师行动包括 HC Wainwright 将其目标价上调至 90 美元，以及 Lifesci Capital 升级至 “强烈买入”。该股票的 1 年价格区间为 13.22 美元至 94.90 美元，市值为 42.4 亿美元</p>

<p>Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has been given a consensus recommendation of &#34;Moderate Buy&#34; by the fourteen brokerages that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $99.1111.</p>
<div class="lb-trans"><p>结构治疗公司（Structure Therapeutics Inc.）赞助的美国存托股票（NASDAQ:GPCR - 获取免费报告）目前获得了 14 家覆盖该股票的券商一致推荐的 “适度买入” 评级，MarketBeat 报道称。两名研究分析师给予该股票卖出评级，十一名给予买入评级，一名给予强烈买入评级。在过去一年中，给予该股票评级的券商的平均 12 个月目标价为 99.1111 美元。</p>
</div><p>Get <strong>Structure Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>结构治疗</strong> 的提醒：</p>
</div><ul>
<li>Can Roche Challenge Lilly and Novo in the Weight Loss Market?</li>
</ul>
<div class="lb-trans"><ul>
<li>罗氏能否在减肥市场挑战礼来和诺和诺德？</li>
</ul>
</div><p>A number of equities research analysts recently weighed in on GPCR shares. HC Wainwright raised their price target on Structure Therapeutics from $60.00 to $90.00 and gave the company a &#34;buy&#34; rating in a report on Friday, December 19th. Lifesci Capital upgraded shares of Structure Therapeutics to a &#34;strong-buy&#34; rating in a report on Monday, September 8th. Citigroup restated an &#34;outperform&#34; rating on shares of Structure Therapeutics in a report on Friday, December 12th. Piper Sandler reissued an &#34;overweight&#34; rating on shares of Structure Therapeutics in a report on Tuesday, October 28th. Finally, Zacks Research lowered Structure Therapeutics from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research report on Friday, October 17th.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 GPCR 股票进行了评估。HC Wainwright 在 12 月 19 日的报告中将结构治疗的目标价从 60.00 美元上调至 90.00 美元，并给予该公司 “买入” 评级。Lifesci Capital 在 9 月 8 日的报告中将结构治疗的股票升级为 “强烈买入” 评级。花旗集团在 12 月 12 日的报告中重申了对结构治疗股票的 “跑赢大盘” 评级。Piper Sandler 在 10 月 28 日的报告中重新发布了对结构治疗股票的 “增持” 评级。最后，Zacks Research 在 10 月 17 日的研究报告中将结构治疗的评级从 “持有” 下调至 “强烈卖出”。</p>
</div><p><strong>Check Out Our Latest Analysis on Structure Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对结构治疗的最新分析</strong></p>
</div><h2>Structure Therapeutics Trading Down 1.9%</h2>
<div class="lb-trans"><h2>结构治疗股票下跌 1.9%</h2>
</div><ul>
<li>Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德的挫折不会持续：一款改变游戏规则的药物出现</li>
</ul>
</div><p>GPCR stock opened at $69.95 on Thursday. The business's 50 day moving average is $41.18 and its 200-day moving average is $28.21. Structure Therapeutics has a 1-year low of $13.22 and a 1-year high of $94.90. The firm has a market cap of $4.24 billion, a P/E ratio of -57.33 and a beta of -1.64.</p>
<div class="lb-trans"><p>GPCR 股票在周四开盘价为 69.95 美元。该公司的 50 日移动平均线为 41.18 美元，200 日移动平均线为 28.21 美元。结构治疗的 1 年最低价为 13.22 美元，1 年最高价为 94.90 美元。该公司的市值为 42.4 亿美元，市盈率为-57.33，贝塔值为-1.64。</p>
</div><p>Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.01). Sell-side analysts forecast that Structure Therapeutics will post -0.82 EPS for the current year.</p>
<div class="lb-trans"><p>结构治疗（NASDAQ:GPCR - 获取免费报告）最近在 11 月 6 日发布了其财报。公司报告季度每股收益（EPS）为（0.37）美元，低于市场共识预期的（0.36）美元，差距为（0.01）美元。卖方分析师预测结构治疗在本年度将发布-0.82 美元的每股收益。</p>
</div><h2>Institutional Trading of Structure Therapeutics</h2>
<div class="lb-trans"><h2>结构治疗的机构交易</h2>
</div><ul>
<li>Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?</li>
</ul>
<div class="lb-trans"><ul>
<li>Altimmune 股票：它的 GLP-1 药物是下一个 Ozempic 杀手吗？</li>
</ul>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. increased its position in shares of Structure Therapeutics by 6.1% in the first quarter. Invesco Ltd. now owns 394,386 shares of the company's stock valued at $6,827,000 after acquiring an additional 22,619 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Structure Therapeutics during the first quarter worth approximately $249,000. Jump Financial LLC bought a new stake in Structure Therapeutics in the 1st quarter valued at $532,000. Trexquant Investment LP grew its stake in shares of Structure Therapeutics by 127.6% in the first quarter. Trexquant Investment LP now owns 120,340 shares of the company's stock valued at $2,083,000 after acquiring an additional 67,464 shares in the last quarter. Finally, DAFNA Capital Management LLC grew its position in shares of Structure Therapeutics by 66.2% during the 1st quarter. DAFNA Capital Management LLC now owns 59,000 shares of the company's stock worth $1,021,000 after purchasing an additional 23,500 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Invesco Ltd.在第一季度将其在结构治疗的持仓增加了 6.1%。Invesco Ltd.目前拥有 394,386 股该公司的股票，价值 6,827,000 美元，此前在上个季度增持了 22,619 股。Quantbot Technologies LP 在第一季度获得了结构治疗的新股份，价值约 249,000 美元。Jump Financial LLC 在第一季度购买了结构治疗的新股份，价值 532,000 美元。Trexquant Investment LP 在第一季度将其在结构治疗的持仓增加了 127.6%。Trexquant Investment LP 目前拥有 120,340 股该公司的股票，价值 2,083,000 美元，此前在上个季度增持了 67,464 股。最后，DAFNA Capital Management LLC 在第一季度将其在结构治疗的持仓增加了 66.2%。DAFNA Capital Management LLC 目前拥有 59,000 股该公司的股票，价值 1,021,000 美元，此前在上个季度增持了 23,500 股。91.78% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>Structure Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>结构治疗公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.</p>
<div class="lb-trans"><p>结构治疗（NASDAQ: GPCR）是一家临床阶段的生物技术公司，专注于发现和开发针对 G 蛋白偶联受体（GPCRs）的口服小分子疗法。该公司利用结构生物学、计算化学和药物化学的进展，科学平台旨在优化结合相互作用和药代动力学特性，目标是提供创新的代谢和炎症疾病治疗方案。</p>
</div><p>The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于临床前和临床开发不同阶段的项目。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Structure Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比结构治疗更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘记 AI 吧，这将是下一个重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1BDUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=GPCR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Structure Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在结构治疗吗？</h2>
</div><p>Before you consider Structure Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑结构治疗之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而结构治疗并不在名单上。</p>
</div><p>While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然结构治疗目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Structure Therapeutics Inc. 赞助的美国存托凭证（NASDAQ:GPCR）被券商一致推荐为 “适度买入”